View Older Stories View More Recent Stories

Sep 19, 2021 06:22PM Merck's (MRK) KEYTRUDA Plus Chemotherapy Reduced Risk of Death by 27% vs Chemotherapy as First-Line Treatment for Metastatic Triple-Negative Breast Cancer Where Tumors Expressed PD-L1
Sep 19, 2021 07:30AM Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer Whose Tumors
Sep 18, 2021 09:05AM Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Superior Recurrence-Free Survival (RFS) in Patients With Resected High-Risk Stage II Melanoma Compared to Placebo in the Adjuvant Setting
Sep 18, 2021 09:05AM Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Death by One-Third Versus Chemotherapy With or Without Bevacizumab as First-Line Treatment for Persis
Sep 17, 2021 07:16AM Merck (MRK) Announces Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Br
Sep 17, 2021 07:15AM Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Ca
Sep 8, 2021 06:45AM Merck To Present New Data From Its Broad Oncology Portfolio and Pipeline at ESMO 2021, Including in Earlier Stages of Cancer
Sep 7, 2021 09:15AM Illumina (ILMN) Partners with Merck (MRK) to Develop and Commercialize Companion Diagnostic and Research Tests for Use in Identifying Specific Cancer Mutations
Sep 7, 2021 06:46AM Merck (MRK) KEYTRUDA® Approved in China in Combination With Chemotherapy Treatment of Locally Advanced Unresectable or Metastatic Esophageal or Gastroesophageal Junction (GEJ) Carcinoma
Sep 7, 2021 06:45AM Merck to Present at the Morgan Stanley 19th Annual Healthcare Conference
Sep 7, 2021 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy for First-Line Treatment of Patients With Locally Advanced Unresectable or Metastatic Esophageal or Gastroesopha
Sep 1, 2021 06:45AM Merck (MRK) And Ridgeback Initiate Pivotal Phase 3 MOVe-AHEAD Study Evaluating Molnupiravir for Post-Exposure Prophylaxis of COVID-19 Infection
Sep 1, 2021 06:45AM Merck and Ridgeback Biotherapeutics Announce Initiation of Pivotal Phase 3 MOVe-AHEAD Study Evaluating Molnupiravir for Post-Exposure Prophylaxis of COVID-19 Infection
Aug 31, 2021 04:06PM FDA Approves Updated Indication for Merck's (MRK) KEYTRUDAfor Treatment of Certain Patients With Urothelial Carcinoma
Aug 31, 2021 04:05PM FDA Approves Updated Indication for Merck’s KEYTRUDA® (pembrolizumab) for Treatment of Certain Patients With Urothelial Carcinoma (Bladder Cancer)
Aug 26, 2021 06:50AM Merck (MRK) KEYTRUDA Receives Two New Approvals in Japan
Aug 26, 2021 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Receives Two New Approvals in Japan
Aug 25, 2021 06:47AM Merck (MRK) Announces VAXNEUVANCE Met Key Immunogenicity and Safety Endpoints in Phase 3 Pivotal Trial Evaluating Use in Infants, PNEU-PED (V114-029)
Aug 25, 2021 06:45AM Merck Announces VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Met Key Immunogenicity and Safety Endpoints in Phase 3 Pivotal Trial Evaluating Use in Infants, PNEU-PED (V114-029)
Aug 20, 2021 04:46PM Merck (MRK) Announces Resignation of Leslie A. Brun from Board
Aug 20, 2021 04:45PM Leslie A. Brun Resigns from Merck Board of Directors
Aug 16, 2021 05:11AM Merck's (MRK) WELIREG™ (belzutifan) Approved by FDA for Treatment of Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors
Aug 13, 2021 07:00PM FDA Approves Merck’s Hypoxia-Inducible Factor-2 Alpha (HIF-2α) Inhibitor WELIREG™ (belzutifan) for the Treatment of Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumor
Aug 12, 2021 05:35AM FDA Approves Merck's (MRK) KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination for First-Line Treatment of Adult Patients with Advanced RCC
Aug 11, 2021 06:30PM FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination for First-Line Treatment of Adult Patients With Advanced Renal Cell Carcinoma (RCC)
Aug 11, 2021 07:05AM IMV Inc. Announces Second Quarter 2021 Financial and Operational Results
Aug 10, 2021 06:45AM FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) as Single Agent for Certain Patients With MSI-H/dMMR Advanced Endometrial Carcinoma
Aug 10, 2021 06:43AM Merck's (MRK) KEYTRUDA® (pembrolizumab) Granted FDA Priority Review as Adjuvant Therapy in Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery
Aug 10, 2021 06:42AM FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) as Adjuvant Therapy in Certain Patients With Renal Cell Carcinoma (RCC) Following Surg
Aug 5, 2021 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Significantly Prolonged Recurrence-Free Survival (RFS) Compared to Placebo as Adjuvant Therapy for Patients With Stage II Resected High-Risk Melanoma in Phase 3 KE
Jul 29, 2021 12:30PM Merck Announces Appointment of Cristal N. Downing as Chief Communications & Public Affairs Officer
Jul 29, 2021 06:30AM Merck Announces Second-Quarter 2021 Financial Results
Jul 27, 2021 01:34PM Merck Announces Fourth-Quarter 2021 Dividend
Jul 27, 2021 06:46AM Merck (MRK) Announces Phase 3 KEYNOTE-355 Trial Met Primary Endpoint of Overall Survival (OS) in Patients with Metastatic Triple-Negative Breast Cancer Whose Tumors Expressed PD-L1
Jul 27, 2021 06:45AM Merck Announces Phase 3 KEYNOTE-355 Trial Met Primary Endpoint of Overall Survival (OS) in Patients with Metastatic Triple-Negative Breast Cancer Whose Tumors Expressed PD-L1 (CPS ≥10)
Jul 27, 2021 06:33AM Merck (MRK) Announces FDA Approves KEYTRUDA for Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy as Neoadjuvant Treatment
Jul 27, 2021 06:30AM FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as
Jul 22, 2021 06:46AM Merck (MRK) Announces FDA Approves KEYTRUDA Plus LENVIMA Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
Jul 22, 2021 06:45AM FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
Jul 21, 2021 07:14AM Merck (MRK) Announces VERQUVO Approved in the European Union
Jul 21, 2021 07:14AM VERQUVO® (vericiguat) Approved in the European Union
Jul 20, 2021 06:11AM Merck (MRK) Presents New Data from Ongoing Phase 2a Trial Evaluating Safety, Tolerability and Pharmacokinetics of Investigational, Once-Monthly, Oral Islatravir for HIV-1 Prevention at IAS
Jul 20, 2021 06:00AM Merck Presents New Data from Ongoing Phase 2a Clinical Trial Evaluating the Safety, Tolerability and Pharmacokinetics of Investigational, Once-Monthly, Oral Islatravir for HIV-1 Prevention at IAS 2021
Jul 19, 2021 08:12AM Ligand's (LGND) Partner Merck (MRK) Receives FDA Approval for VAXNEUVANCE for the Prevention of Invasive Pneumococcal Disease in Adults Caused by 15 Serotypes
Jul 19, 2021 07:23AM Merck (MRK) Announces FDA Approval of VAXNEUVANCE to Prevent Invasive Pneumococcal Disease
Jul 16, 2021 05:15PM Merck Announces U.S. FDA Approval of VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Adults 18 Years and Older Caused by 15 Serotypes
Jul 15, 2021 01:30PM KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Showed Statistically Significant Event-Free Survival (EFS) Result Versus Neoadjuvant Chemother
Jul 12, 2021 07:00AM Merck (MRK) to Present New Data from Broad HIV Program at IAS 2021
Jul 12, 2021 06:55AM Merck Announces Presentation of New Data from Broad HIV Program at IAS 2021
Jul 12, 2021 06:46AM Merck (MRK) Announces Interim Results from Phase 2/3 Studies of Molnupiravir, an Investigational Oral Antiviral Therapeutic for Mild to Moderate COVID-19, Presented at ECCMID
View More Recent Stories View Older Stories